Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elasomeran + imelasomeran (Moderna Inc, 10648a)
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1273.214 (elasomeran + imelasomeran) is a bivalent messenger RNA (mRNA) vaccine developed by Moderna to provide protection against COVID-19. It is a 1:1 combination of two mRNA candidates: mRNA-1273 (elasomeran), which encodes the prefusion-stabilized spike (S) glycoprotein of the ancestral SARS-CoV-2 strain (Wuhan-Hu-1), and mRNA-1273.529 (imelasomeran), which encodes the spike protein of the Omicron BA.1 variant. The vaccine is encapsulated in lipid nanoparticles (LNPs) and is designed to elicit a broader neutralizing antibody response against circulating variants of concern compared to the original monovalent vaccine. Clinical trials demonstrated that a 50-μg booster dose of mRNA-1273.214 met all primary endpoints, showing superior immunogenicity against Omicron BA.1 while maintaining a safety profile consistent with the original Spikevax vaccine.
- Other names
- mRNA-1273.529 + mRNA-1273.214Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.1)Bivalent Omicron-containing booster vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on elasomeran + imelasomeran (Moderna Inc, 10648a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elasomeran + imelasomeran (Moderna Inc, 10648a).